|Genfit SA -- USA Stock|| |
USD 30.78 0.43 1.38%
Member of the Supervisory Board, Representative of Finorpa
Mr. Philippe Moons has served as Member of the Supervisory Board, Representative of Finorpa at Genfit SA since September 15, 1999. Within the Company, he is Chairman of the Audit Committee. He began his professional career with Finorpa in 1989 and, in 1995, he was appointed to the position of Director of the Lille office. In 2004, he became Director of the Business Service division.
Executive Since 1999
33 3 20 16 40 00 http://www.genfit.com
The company has return on total asset (ROA)
of (21.4) %
which means that it has lost $21.4 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (41.34) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 10.6 M in total debt with debt to equity ratio (D/E) of 7.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Genfit SA has Current Ratio of 7.18 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular focus on the liver worldwide. Genfit SA was founded in 1999 and is headquartered in Loos, France. Genfit SA is traded on OTC Market in USA.Genfit SA (GNFTF) is traded on OTC Market in USA. It is located in Parc Eurasant? and employs 120 people.